Semaglutide (Ozempic) shows potential for treating addiction and dementia
The Guardian — May 14, 2024, 06:00 PM UTC
Summary: Semaglutide, known as Ozempic or Wegovy, is a versatile drug showing benefits beyond diabetes and weight loss. Studies indicate it improves blood sugar control in type 2 diabetes patients. For weight loss, it led to an average loss of 15.3kg in overweight adults. It may also reduce heart attack risk by 20% and potentially benefit those at risk of dementia and addiction. Studies on its impact on PCOS and cancer are ongoing.
Article metrics
The article metrics are deprecated.
I'm replacing the original 8-factor scoring system with a new and improved one. It doesn't use the original factors and gives much better significance scores.